Compare AstraZeneca plc (AZN) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Expeditors International of Wshngtn Inc — how do they compare? AstraZeneca plc trades at $166.95 (market cap $253.13B), while Expeditors International of Wshngtn Inc trades at $178.61 (market cap $23.31B). The key difference: AstraZeneca plc is far larger — about 10.9× Expeditors International of Wshngtn Inc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | EXPD | |
|---|---|---|
Market Cap | $253.13B | $23.31B |
Sector | Health | Industrials |
52-Week High | $209.48 | $178.22 |
52-Week Low | $137.44 | $111.37 |
Enterprise Value | $279.37B | $22.56B |
Dividend Yield | 1.92% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
EXPD trades at $175.50, up 2.02% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, revenue growth to $11.07B in 2025, and impressive ROE of 36.59%. Recent dividend payments and positive analyst coverage highlight financial stability, though valuation metrics appear elevated with P/E of 28.35.
Outlook remains positive with earnings momentum and e-commerce tailwinds, but risks include stretched valuation, mixed analyst sentiment (only 12% buy ratings), and economic sensitivity. The stock trades above consensus price target of $159, suggesting limited near-term upside potential despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
